...
首页> 外文期刊>Oncoimmunology. >Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity
【24h】

Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity

机译:癌症化学治疗剂靶向肿瘤内树突状细胞以增强抗肿瘤免疫力

获取原文
获取原文并翻译 | 示例
           

摘要

Cytotoxic drugs capable of killing cancer cells in conjunction with targeted conversion of tumor resident, tolerogenic dendritic cells (DCs) into efficient antigen presenting cells (APCs) are highly complementary therapeutic routes to boost antitumor immunity. Our data suggest that the microtubule-depolymerizing compounds Dolastatin 10 and Ansamitocin P3 may serve as prototypes for a class of agents that display this binary mode of action.
机译:能够杀死癌细胞的细胞毒性药物与将肿瘤驻留的致耐受性树突状细胞(DC)定向转化为有效的抗原呈递细胞(APC)相结合,是增强抗肿瘤免疫力的高度互补的治疗途径。我们的数据表明,微管解聚化合物Dolastatin 10和Ansamitocin P3可以作为一类展示这种二元作用模式的药物的原型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号